Laurus Labs posted strong Q1 FY26 growth, driven by CDMO surge, margin gains, and strategic expansion in Andhra Pradesh.

• CDMO revenue doubled YoY to Rs 522 crore, while FDF rose 50%, supporting robust business performance.
• EBITDA jumped 127% to Rs 389 crore; margins expanded due to operating leverage and better CDMO product mix.
• Andhra Pradesh allotted 531.77 acres for Rs 5,630 crore Laurus Pharma Zone, expected to create 6,350 jobs.